GSA Capital Partners’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-930,718
| Closed | -$1.37M | – | 2017 |
|
|
2022
Q2 | $1.37M | Buy |
930,718
+462,882
| +99% | +$340K | 0.21% | 55 |
|
|
2022
Q1 | $538K | Buy |
467,836
+343,336
| +276% | +$560K | 0.07% | 476 |
|
|
2021
Q4 | $311K | Buy |
124,500
+52,848
| +74% | +$208K | 0.04% | 908 |
|
|
2021
Q3 | $367K | Buy |
+71,652
| New | +$435K | 0.04% | 893 |
|
|
2021
Q2 | – | Sell |
-64,143
| Closed | -$559K | – | 1706 |
|
|
2021
Q1 | $559K | Buy |
+64,143
| New | +$664K | 0.09% | 293 |
|
|
2020
Q4 | – | Sell |
-79,582
| Closed | -$949K | – | 1730 |
|
|
2020
Q3 | $949K | Buy |
+79,582
| New | +$1.07M | 0.16% | 112 |
|
|
2019
Q2 | – | Sell |
-24,742
| Closed | -$307K | – | 1833 |
|
|
2019
Q1 | $307K | Sell |
24,742
-18,024
| -42% | -$202K | 0.03% | 977 |
|
|
2018
Q4 | $263K | Buy |
+42,766
| New | +$327K | 0.03% | 917 |
|
|
2017
Q2 | – | Sell |
-22,000
| Closed | -$377K | – | 2034 |
|
|
2017
Q1 | $377K | Buy |
+22,000
| New | +$293K | 0.02% | 1263 |
|
|
2016
Q4 | – | Sell |
-38,860
| Closed | -$382K | – | 2027 |
|
|
2016
Q3 | $382K | Buy |
+38,860
| New | +$355K | 0.02% | 1213 |
|
Other funds holding EPZM
GSA Capital Partners's EPZM Position: Q3 2022 in Review
GSA Capital Partners sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 930,718 shares — an estimated $1.37M sold.
GSA Capital Partners first reported a position in EPZM in Q3 2016 and held it in 10 quarters. The position peaked at $1.37M in Q2 2022. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- GSA Capital Partners reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- GSA Capital Partners sold 930,718 Epizyme, Inc shares in Q3 2022, an estimated $1.37M.
- GSA Capital Partners first reported a position in Epizyme, Inc in Q3 2016 and held it in 10 quarters.
- GSA Capital Partners's Epizyme, Inc position peaked at $1.37M in Q2 2022.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on GSA Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.